August 20, 2018

To	To
Listing Department,NATIONAL STOCK EXCHANGE OF INDIA LIMITEDExchange Plaza,Bandra Kurla Complex, Bandra (E),MUMBAI -400 051	The Corporate Relations DepartmentBSE LIMITEDPhiroz Jeejeebhoy Towers,25th floor, Dalal Street,MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sirs,

Sub: Analysts / Investors Meet.

We would like to inform you that we are attending investor conference hosted by Citi Group from 21st August, 2018 to 23rd August, 2018 in Hong Kong and Singapore and as part of it, we will be meeting several investors. The attached presentation will be used in the aforesaid investor conference.

The presentation is also being uploaded on the website of the Company –

http://www.aurobindo.com/investor-relations/investors/investor-presentation

Please take the information on record.

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

LEADING VERTICALLY INTEGRATED GENERIC PLAYER

August 2018

This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any part hereof, form the basis of, or be relied on in connection with, any contract therefore.

This presentation contains statements that constitute "forward looking statements" including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance.

While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance.

Aurobindo Pharma undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances.

This document is strictly confidential and may not be disclosed, reproduced or redistributed, in whole or in part, to any other person.

For updates and specific queries, please visit our website www. aurobindo.com

Emerged into a leading global generic player

The Journey So Far…

2006-08

Acquired UK based Milpharm
Acquired formulations facility, AuroLife, in US

2009-12

Commenced Aurolife operations
Received first approval for controlled substance drug in US

2013

Commenced marketing specialty injectables in USA
Building capabilities in Penem and Oncology

2006 - 2013

Formulation Focus

+ Establishing Global Footprint

2014

Acquired Western European commercial operations from Actavis
Acquired Natrol (Consumer Healthcare)

2015-16

Established OTC presence
Entered into Biosimilars and Vaccines
Filed first peptide DMF

2017-18

Acquired Generis in Portugal
Focus on differentiated technology platforms and Specialty Pharmaceuticals
Entered into a definitive agreement to acquire Apotex Inc's commercial operations in 5 European countries

2014-2018

Strengthening market penetration in the US & EU + Expanding into Specialty Products

1992-2006

Started API manufacturing
Initial Public Offering ('95)
Entered formulation business ('02)

Pre-2006

Core Strengths

Scale, Diversity & Leadership

Among Top 3 in >60% of commercial portfolio in US(1) in terms of prescriptions
Large US portfolio(2) - 487 ANDAs filed; 342with final approval, 33 Tentative approval(3), and 112 under review
Strong foothold in the US and EU (~45% and ~26% of revenue in FY18)
Extensive product portfolio & pipeline
Experienced and forwardlooking leadership team

Operational Strengths

Large manufacturing facilities inspected and approved by US FDA, EMA, and other regulators
Dedicated, cutting-edge global R&D Centers for diverse technology platforms and APIs
Focus on complying with quality and EHS standards
Speed and effectiveness in execution

Patient Focus

Unwavering commitment to bring access to highquality, low-cost generics to patients globally
Continuous effort to maximize patient reach
Continue to offer a broad, cost-competitive portfolio for all consumer needs

Diversified Revenue Base & Strong Organic growth

US Business Overview

US Business – Segment Wise Highlights

Orals – Aurobindo Pharma USA

73% of overall US business in FY18
261 approved ANDAs, 31(1) TAs, and 72 under review**
Future pipeline includes
Controlled substances with ADF
Oncology
505b2 products for selected patient segments

OTC – AuroHealth

Entered the market in 2015
Launched the first set of key products in 2017
23 approved ANDAs and 5 under review**
Future pipeline includes
Rx to OTC switch opportunities
Branded OTC

Injectables - AuroMedics

14% of overall US business in FY18
3 rd largest Gx injectable company by volume*
58 approved ANDAs, 2 TAs, and 35 under review**
Future pipeline includes
- Complex injectables including microspheres
- Oncology
- Hormones

Dietary Supplements – Natrol

A trusted leader in health & wellness for 35-years known for outstanding people, uncompromising quality, innovation, customer service and efficiency
Robust product portfolio of 210 proprietary, science based formulas across nine segments and multiple product forms
#1 in Melatonin and strong positions in Beauty, Mood, and Brain Health
A growing international enterprise doing business in 60 countries
Best in class, blue chip customers. Growth opportunities in every channel

EU Business Overview

India's Leading Gx company with strong footprint in Europe
- Operations in 9 countries with full fledged Pharmacy, Hospital and Tender sales infrastructure with commercialized 450+ INNs
- Ranks amongst the Top 10 Gx companies in four out of Top-5 EU countries. France & Germany are top 2 markets for the company
- Turned around loss-making business units through increasing a) switch to cost-competitive manufacturing locations and, b) operational efficiencies
Completed acquisition of Generis Farmaceutica SA; catapulting APL group to # 1 position by value and volume in the Portuguese Gx market
Completed acquisition of Orocal brand; to bolster Growth Drivers Pharmacy products portfolio of Arrow France

Revenue

Portfolio Expansion through targeted Day 1 launches; Orals, Hormones, Penems, Oncology Products and Niche Low volume Injectables. Pipeline of over 250 products under development
Opportunity of > $ 8 Bn of addressable sales coming off patent in our key markets in near term (2018-2020) and > $ 13 Bn in the medium term (2021-2022)#
Future growth potential in countries like Italy, Spain, Portugal & France as penetration of generics improve
Expanding into new geographies viz. Poland and Czech Republic

EU: Portfolio Mix Across Channels

Channels	Gx	BGx	Hx	TGx
Geographies	All 9 countries	7 countries	All 9 countries	Germany, Spain& Netherlands
# of Products	769 (primarilytablets& capsules)	37	347 (predominantlyinjectables)	767 (including Gxproducts)
Other Highlights	Amongst top 10 inmost significantmarkets	Includes leading brandssuch as Orocal(1),Neotigason, Floxapen,Bezalipamong others	Focus onhigh valueareas includingoncology	Tender basedbusiness

ARV & Growth Markets Business Overview

ARV Business

Comprehensive portfolio of 32 products with a robust pipeline for the future
Dolutegravir based regimens are expected to attain ~59% market share by 2021 as per CHAI** report
The HIV patient reach is expected to improve to ~5 Mn by FY19 from current level of ~3Mn

Revenue

Growth Markets Business

Build branded generics presence in key markets
Expand in selected markets through local manufacturing
Product launches in Oncology and specialty injectables

The Base Business : API

API capacity is strategic in-terms of vertical integration and supply to regulated markets; Additional investments are made for capacity creation and capability building
API business continue to focus on complex products with varying volumes
Focus on continuous improvement of manufacturing processes to meet market needs
Continue to have sustained growth in more advanced regulated markets (EU, Japan & USA)
API facilities have been inspected by USFDA, UK MHRA, EU, Japan PMDA, Mexico COFEPRIS, Brazil-ANVISA, Korea FDA etc.

Significant increase in reaction volumes

Financial Performance

EBITDA & PAT Margin (%) EPS (INR/Share)

Gross Block & Fixed Asset Turnover Net debt / Equity Net Debt/EBITDA

Shifting Paradigms ...

Focus on Building a Diverse and Robust Specialty Products Portfolio

Enhanced Research & Development Capabilities

5 R&D centers in Hyderabad, India >1500 scientists and analysts

Focused on difficult to develop APIs, peptides, etc.
Develop modern process technologies like enzyme chemistry
Dosage Form R&D for developing niche oral, sterile and specialty injectable products
Developing diverse pipeline of biosimilars in Oncology and Immunology. CHO-GS based cell lines with productivity of ~ 4.0 g/L
Portfolio of more than 800 products

1 R&D center in Dayton, New Jersey – 25 scientists and analysts

Developing depot injectable and tamper/abuse-resistant technology products
Concentrating on development of various niche oral formulation and controlled substances
Portfolio of more than 30 products

1 R&D center in Raleigh, North Carolina – 40 scientist and analysts

Developing various respiratory and nasal products, including MDIs
Dermal Delivery portfolio including transdermal and topical products
Portfolio of more than 40 products

All R&D centres have world-class talent and are equipped with state of the art infrastructure

Supported by well qualified and trained Regulatory and Intellectual Property teams

R&D Spend – $ Mn (as % of revenue)

Thank You